ArticleScientific reports2025
The aggregate index of systemic inflammation (AISI) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in congestive heart failure patients: results from NHANES 1999-2018.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The predictive role of early and late-stage inflammatory markers in the development of retinopathy of prematurity in discordant twins.Eye (London, England) · 2026Article
- Comparison of Novel Systemic Inflammatory Indices for Identification of Left Ventricular Hypertrophy in Hypertensive Patients: A Large-Scale Cross-Sectional Study in China.Journal of cardiovascular development and disease · 2026Article
- The Limited Diagnostic Utility of Metabolic and Inflammatory Indices in Adolescent Polycystic Ovary Syndrome: A Case-Control Study.Biomedicines · 2026Article
- CBC-derived inflammatory indices predict adverse outcomes in geriatric emergency patients with acute infectious diarrhea: a MIMIC-IV analysis.Scientific reports · 2026Article
- Positive relationship between an aggregate index of systemic inflammation and stress urinary incontinence: a nationwide cross-sectional analysis.Translational andrology and urology · 2026Article
- Joint association of estimated glucose disposal rate and aggregate index of systemic inflammation with mortality in general population: a nationwide prospective cohort study.Cardiovascular diabetology · 2026Article
- Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study.Frontiers in cardiovascular medicine · 2026Article
- Inflammatory indices AISI and SIRI in atherosclerosis risk stratification: validation across community and intensive care populations.Annals of medicine · 2025Article
- The association between the aggregate index of systemic inflammation and abdominal aortic calcification: a National health and nutrition examination survey.Journal of cardiothoracic surgery · 2025Article
- Relationship between aggregate index of systemic inflammation and mortality from CCD and malignant neoplasms in diabetic patients.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congestive heart failure (CHF) is a prevalent cardiovascular disease, with increasing incidence and mortality rates associated with aging populations and rising rates of chronic diseases. Systemic inflammatory response is recognized to play a pivotal role in the pathogenesis of CHF, and the aggregate index of systemic inflammation (AISI) has garnered widespread attention as a comprehensive indicator reflecting inflammatory status in recent years. However, there is currently a lack of large-scale epidemiological studies investigating the relationship between AISI and all-cause, cardiovascular, and cardio-cerebrovascular mortality risks among CHF patients. This study aims to utilize data from the NHANES database spanning 1999 to 2018 to analyze the association between AISI and prognosis in CHF patients, aiming to provide new evidence to support research into the pathophysiology and clinical management of CHF. This study enrolled 1624 patients aged ≥ 18 years with congestive heart failure (CHF) from the National Health and Nutrition Examination Survey spanning 1999 to 2018. Patients were stratified into four groups based on the aggregate index of systemic inflammation (AISI). Survival differences among the groups were compared using log-rank tests and Kaplan-Meier curves. Additionally, multivariable Cox regression and restricted cubic spline analyses were employed to explore the relationship between AISI and all-cause, cardiovascular, and cardio-cerebrovascular mortality. Overall, during a mean follow-up of 76.4 ± 56.6 months among patients with congestive heart failure, a total of 828 participants (51.042%) died. Among these, 314 (19.389%) deaths were attributed to cardiovascular diseases, and 344 (21.226%) were related to cardio-cerebrovascular mortality. Kaplan-Meier analysis revealed significant differences in all-cause, cardiovascular, and cardio-cerebrovascular mortality among AISI quartiles (log-rank test: all P < 0.001). Multivariable adjusted models demonstrated that participants in the highest AISI quartile had increased risks of all-cause mortality (hazard ratio [HR] = 1.599, 95% confidence interval [CI] 1.595-1.602), cardiovascular mortality (HR = 1.070, 95% CI 1.066-1.074), and cardio-cerebrovascular mortality (HR = 1.173, 95% CI 1.168-1.177) compared to those in the lowest quartile. Additionally, restricted cubic spline analysis indicated a nonlinear association between AISI and all-cause mortality (P = 0.0064), with an inflection point at AISI 8.66. On the left flank of the inflection point, each twofold increase in AISI was associated with a 19.6% higher risk of all-cause mortality (HR = 1.196, 95% CI 0.930-1.538), while on the right flank, there was a 126.2% increase (HR = 2.262, 95% CI 1.506-3.395). Furthermore, each twofold change in AISI was nonlinearly associated with a 60.2% higher risk of cardiovascular mortality (HR = 1.602, 95% CI 1.075-2.388) and a 56.6% higher risk of cardio-cerebrovascular mortality (HR = 1.566, 95% CI 1.072-2.286). E-value analysis suggested robustness to unmeasured confounding. In the population of patients with congestive heart failure aged 18 years and older in the United States, irrespective of established risk factors, AISI was significantly associated with all-cause, cardiovascular, and cardio-cerebrovascular mortality. Further research is needed to validate this.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.